Vericiguat for Heart Failure With Reduced Ejection Fraction After Myocardial Infarction

Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Dec 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called vericiguat to see how it affects patients with heart failure after a heart attack. Heart failure with reduced ejection fraction (HFrEF) means that the heart is not pumping blood as well as it should. The trial will involve patients who have stable heart failure symptoms for at least a month after their heart attack. To be eligible, participants must be at least 18 years old, have a history of heart attack that happened more than three months ago, and have specific heart function measurements.

In this study, participants will be divided into two groups: one will receive vericiguat along with standard treatment for heart failure, while the other group will only receive the standard treatment. Over a period of 12 months, researchers will evaluate how well the medication works and whether it causes any side effects. This trial aims to provide valuable information that could lead to new treatment options for people living with heart failure after a heart attack. If you or a loved one meet the criteria and are interested in participating, you'll need to sign a consent form before joining the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The history of acute myocardial infarction exceeds 3 months;
• • 2. Symptoms and signs of heart failure have been stable for more than one month;
• • 3. 18 years old or more;
• • 4. NYHA cardiac function classified as grade II\~IV;
• • 5. LVEF≤40%；
• • 6. NT-proBNP≥450pg/ml；
• • 7. All subjects or their guardians must sign the subject consent before entering the trial.
• Exclusion Criteria:
• • 1. Patients with the following diseases: nonischemic cardiomyopathy; valvular heart disease; congenital heart disease; obstruction of left ventricular outflow tract; severe decompensated heart failure; active myocarditis or pericardial disease; end-stage liver and kidney diseases; malignant tumor;
• • 2. Mechanical complications of myocardial infarction;
• • 3. Unable to obtain primary outcome data.